BioNumerik Pharmaceuticals

About:

BioNumerik Pharmaceuticals discovers, develops and commercializes drugs for treating cancer.

Top Investors: Takeda

Description:

BioNumerik Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drugs that help in the treatment of cancer. The company’s two oncology drug candidates, Tavocept and BNP1350, are in late-stage clinical development. BioNumerik Pharmaceuticals, Inc. was founded in 1992 and is based in San Antonio, Texas.

Total Funding Amount:

$63.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Antonio, Texas, United States

Founded Date:

1992-01-01

Contact Email:

Info(AT)bnpi.com

Founders:

Frederick H. Hausheer

Number of Employees:

51-100

Last Funding Date:

2012-11-08

IPO Status:

Private

Industries: